These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 790125)

  • 41. [Lamuran dragées in the treatment of torpid ulcerations of the leg (author's transl)].
    Smeral R
    Cesk Dermatol; 1979 Oct; 54(5):295-7. PubMed ID: 527062
    [No Abstract]   [Full Text] [Related]  

  • 42. [Effect of almitrine/raubasine on cerebral metabolism in the elderly].
    Allain H; Bentué-Ferrer D
    Presse Med; 2002 Mar; 31(12):562-4. PubMed ID: 11984975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memory disorders in 8,037 elderly patients with age-associated memory impairment: multicenter trial with a 6-month follow-up under almitrine-raubasine.
    Poitrenaud J; Laurent B; Sebban C
    Eur Neurol; 1995; 35 Suppl 1():43-6. PubMed ID: 8529729
    [No Abstract]   [Full Text] [Related]  

  • 44. Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach.
    Bentué-Ferrer D; Decombe R; Reymann JM; Schatz C; Allain H
    Clin Neuropharmacol; 1990; 13 Suppl 3():S9-25. PubMed ID: 2093421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of a combination of raubasine, dihydroergocristine and dihydroergotamine in dogs and human beings.
    Marzo A; Ghirardi P; Parenti MA; Merlo L; Marchetti G; Cavalca L; Omboni E; Pignataro T; Ligresti A
    Farmaco Prat; 1981 Apr; 36(4):173-97. PubMed ID: 6785104
    [No Abstract]   [Full Text] [Related]  

  • 46. The effects of raubasine and dihydroergocristine on an age-related deficit in passive avoidance learning in rats.
    Chopin P; Briley M
    J Pharm Pharmacol; 1990 May; 42(5):375-6. PubMed ID: 1976794
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term effects and safety of almitrine-raubasine in age-associated cognitive decline.
    Guez D
    Clin Neuropharmacol; 1990; 13 Suppl 3():S109-16. PubMed ID: 2093415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Glycosylated hemoglobin and raubasine in experimental streptozotocin diabetes].
    Loscalzo B; Agrusta A; Agrusta M; Ammaturo V; Crisci A; Genovese L; Marino M
    Boll Soc Ital Biol Sper; 1983 Aug; 59(8):1123-9. PubMed ID: 6626349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Biopharmaceutical studies on meprobamate tables formulation (author's transl].
    Aiache JM; Andermann G
    J Pharm Belg; 1978; 33(3):157-70. PubMed ID: 682102
    [No Abstract]   [Full Text] [Related]  

  • 50. [Bioavailability of raubasine in various pharmaceutical forms in the dog].
    Castoldi D; Chinea B; Montanari P
    Farmaco Prat; 1976 Nov; 31(11):580-5. PubMed ID: 1017471
    [No Abstract]   [Full Text] [Related]  

  • 51. [Delta-yohimbine].
    RAYMOND-HAMET ; GOUTAREL R
    C R Hebd Seances Acad Sci; 1951 Jul; 233(5):431-3. PubMed ID: 14870359
    [No Abstract]   [Full Text] [Related]  

  • 52. [The cerebral blood-flow-volume in patients with sclerotic changes after treatment with raubasin (Lamuran)].
    Klemm J; Scheuring HJ
    Med Klin; 1974 May; 69(21):947-52. PubMed ID: 4602944
    [No Abstract]   [Full Text] [Related]  

  • 53. Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine.
    Sebban C
    Eur Neurol; 1995; 35 Suppl 1():37-42. PubMed ID: 8529728
    [No Abstract]   [Full Text] [Related]  

  • 54. A review of the EEG effects of the combination of almitrine and raubasine in animals and humans.
    Sebban C; Tesolin B; Schatz C; Malbezin M; Guez D
    Clin Neuropharmacol; 1990; 13 Suppl 3():S50-8. PubMed ID: 2093418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evidence for the action of raubasine from a new formulation of Lamuran tablets].
    Glocke M; Grübl M; Klein K; Teufel W
    Med Klin; 1976 Sep; 71(38):1564-8. PubMed ID: 790125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Modification of cerebrovascular diseases through the oral administration of raubasine].
    Klein K; Grübl M
    Wien Med Wochenschr; 1974 Jun; 124(23):360-4. PubMed ID: 4599577
    [No Abstract]   [Full Text] [Related]  

  • 57. [Action of raubasine (new formulation) in arterial occlusive diseases (author's transl)].
    Schütz RM; Teufel W; Glocke M
    Med Klin; 1976 Sep; 71(39):1605-10. PubMed ID: 790128
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.